Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review
Afatinib, the world’s first irreversible ErbB family (containing four different cancer cell epidermal growth factor receptors, including EGFR, HER2, ErbB3, and ErbB4) inhibitor, is a second-generation oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). It can be used as a fir...
Wedi'i Gadw mewn:
| Prif Awduron: | , , , , , |
|---|---|
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
MDPI AG
2023-05-01
|
| Cyfres: | Current Oncology |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.mdpi.com/1718-7729/30/6/405 |
| Tagiau: |
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|